

**National Cancer Policy Forum Workshop Agenda:
Policy Issues in the Development and Adoption of Molecularly Targeted Therapies for Cancer**

November 10, 2014

7:45 am	Registration
8:00 am	Welcome from the IOM's National Cancer Policy Forum: Michael Caligiuri, James Cancer Hospital and Solove Research Institute, OSU Comprehensive Cancer Center Overview of the Workshop: Adrian Senderowicz, Ignyta, Inc.
8:15 am	Session 1 Challenges in developing clinical biomarker tests <i>Moderator: Samir Khleif, Georgia Regents University Cancer Center</i> <i>Lessons learned from single analyte tests</i> Bruce Johnson, Dana Farber Cancer Institute <i>New challenges with next gen sequencing</i> Mia Levy, Vanderbilt University <i>Challenges in analytical validation of NGS tests for clinical trials</i> Mickey Williams, NCI <i>Tests for circulating tumor DNA</i> Matthias Holdhoff, MD, Johns Hopkins University <i>RNAseq Tests</i> Neil Hayes, University of North Carolina-Chapel Hill Group Discussion
10:30 am	Break
10:45 am	Session 2A: Evidentiary Standards: Regulatory Science <i>Moderator: Adrian Senderowicz, Ignyta, Inc.</i> <i>Overview of FDA Regulations for Diagnostics</i> Adrian Senderowicz, Ignyta, Inc. <i>Evolving paradigm for Companion Diagnostics and other Diagnostic Tests at FDA</i> David Litwack, FDA <i>Clinical Utility of Diagnostic Tests</i> David Eberhard, University of North Carolina-Chapel Hill Group Discussion
12:15 pm	Lunch Break
1:00 pm	Session 2B: Evidentiary Standards: Reimbursement <i>Moderator: Robert McDonough, Aetna</i> <i>MolDX approach</i> Dane Dickson, Palmetto, Teton Cancer Institute <i>Payers Perspectives</i> Donna Messner, CMTP Group Discussion
2:00 pm	Session 3A: Generating Evidence: Clinical Trial Designs <i>Moderator: Barbara Conley, NCI</i> <i>LungMap</i> Roy Herbst, Yale University

	<p><i>Matching Drugs to Mutations for Treating Advanced Cancer</i> Lilian Siu, Princess Margaret Hospital, Ontario Cancer Institute,</p> <p><i>Evaluation of NGS for companion diagnostics use</i> Anne-Marie Martin, GSK</p> <p>Group Discussion</p>
3:20 pm	Break
3:30 pm	<p>Session 3B: Generating Evidence: Other Mechanisms <i>Moderator: Richard Schilsky, ASCO</i></p> <p><i>Actionable Genome Consortium</i> David Solit, Memorial Sloan-Kettering Cancer Center</p> <p><i>Coverage with evidence development</i> Sean Tunis, CMTP</p> <p><i>Facilitated drug access program and registry</i> Richard Schilsky, American Society of Clinical Oncology</p> <p><i>Benefits and limitations/challenges of registries/databases</i> Garnet Anderson, Fred Hutchinson Cancer Research Center, University of Washington School of Public Health</p> <p>Group Discussion</p>
5:15 pm	Wrap up Day 1 and Adjourn
November 11, 2014	
7:30 am	Registration
8:00 am	<p>Session 4: Practice Guidelines & Implementation into Clinical Practice <i>Moderator: Roy Herbst, Yale University</i></p> <p><i>Guidelines Development</i> Bill Gradishar, Northwestern University</p> <p><i>Treatment Pathways</i> Jennifer Malin, Wellpoint</p> <p><i>Adoption of genomics in oncology care</i> Kathryn Phillips, UCSF</p> <p><i>Return of sequencing results to patients</i> Patricia LoRusso, Yale University</p> <p>Group Discussion</p>
10:00 am	Break
10:15am	<p>Session 5: The business model for test development <i>Moderator: Lisa McShane, NCI</i></p> <p>Karen Long, Abbott Molecular</p> <p>Federico Monzon, Invitae</p> <p>Group Discussion</p>
11:30 am	Workshop Wrap Up
11:45 am	Adjourn